Enliven Therapeutics, Inc. 4

OrbiMed-affiliated funds sold a total of 281,408 shares of Enliven Therapeutics, Inc. common stock at $45.02 per share on June 15, 2026, for roughly $12.7 million in aggregate proceeds.

On June 15, 2026, OrbiMed-related entities reported two open-market sales of Enliven Therapeutics, Inc. common stock at a price of $45.02 per share. One sale by OrbiMed Genesis Master Fund, L.P. (reported through OrbiMed Genesis GP LLC and OrbiMed Advisors LLC) involved 9,086 shares for proceeds of about $0.4 million, leaving 245,728 shares beneficially owned indirectly. The other sale by OrbiMed Private Investments VII, LP (reported through OrbiMed Capital GP VII LLC and OrbiMed Advisors LLC) involved 272,322 shares for proceeds of about $12.3 million, leaving 7,388,902 shares beneficially owned indirectly. The OrbiMed entities disclaim beneficial ownership beyond their pecuniary interests, noting that voting and investment power is exercised by a management committee whose members also disclaim beneficial ownership.

Filing Facts

CIK

1672619

Ticker

ELVN

Form

4

Source Type

sec

Accession

0000947871-26-000637

Alert Tier

7